HNN3.0
Register
Register
Register

Project cooperationUpdated on 16 December 2025

process development & GMP manufacturing of viral vectors

Grant Projects Director at ReiThera srl

Rome, Italy

About

ReiThera is available to join consortia requiring an SME partner with deep and consolidated expertise in viral vectors for the development of innovative genetic vaccines and medicinal products for advanced therapies.

Our proven capabilities in the viral vectors field range from vector and cell line engineering; scalable manufacturing process development and optimization; GMP production; development of analytical methods and quality control.

Our company can support Projects aimed at clinical translation across multiple viral vector platforms, including adenoviral, vaccinia lineage vectors, AAV, lentiviral, and herpes simplex vectors.

Topic

  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)

Type

  • Partner seeks Consortium/Coordinator

Organisation

ReiThera srl

Company (SME)

Rome, Italy

Similar opportunities

  • Project cooperation

    Adenoviral vaccine platform

    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential

    Angelo Raggioli

    Head of Technology Development at ReiThera srl

    Rome, Italy

  • Project cooperation

    Modified Vaccinia Ankara (MVA) platform for strong T-cell immune responses

    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential

    Angelo Raggioli

    Head of Technology Development at ReiThera srl

    Rome, Italy

  • Project cooperation

    Fisabio - Genomics and Health Research Area

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
    • DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-01: Towards a better understanding and anticipation of the impacts of climate change on health
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions

    Belén Mañogil Sáez

    FISABIO International Projects Unit at FISABIO - Foundation for the Promotion of Health and Biomedical Research of the Valencian Community

    Valencia, Spain